Why would they have this listed as a risk? Article mention how this might even the playing field...that states that Dacogen was surging ahead of Vidaza. A few doctors will experiment with it...but they were already probably using Vidaza...so are they stealing market share from themselves. PHRM will get another quarter where they can point there finger at Vidaza that it will hold it's share. Dacogen alternative dosing is what the doctors are waiting on....and that news is coming.
Actually had a 34% complete response and 19 month survival. This was twice the rate of vidaza. This is why today Supg moved up. When you weight the side effects and the fact that Dacogen help patients when clearly Vidaza couldn't.
Note that Dacogen is still a better product...any drop will be temporary until the MD Anderson Dosing is completed.
Results from a Phase III clinical trial demonstrated an overall response rate of 21% in Dacogen-treated patients considered evaluable for response, compared to 0% in the supportive care arm; PHRM's Vidaza showed an overall response rate of 16%. Firm says that the FDA approval of Dacogen marks an important advancement for patients who suffer from MDS, and Dacogen will thus be a welcome addition to the repertoire of drugs for select patients with MDS.